Potential anti-cancer activity of Moringa oleifera derived bio-active compounds targeting hypoxia-inducible factor-1 alpha in breast cancer
Author:
Masarkar Neha1, Ray Suman Kumar2, Saleem Zirha3, Mukherjee Sukhes1
Affiliation:
1. Department of Biochemistry , All India Institute of Medical Sciences , Bhopal , Madhya Pradesh , India 2. Independent Researcher , Bhopal , Madhya Pradesh , India 3. Department of Biotechnology , Institute for Excellence in Higher Education , Bhopal , Madhya Pradesh , India
Abstract
Abstract
Breast cancer (BC) will become a highly detected malignancy in females worldwide in 2023, with over 2 million new cases. Studies have established the role of hypoxia-inducible factor-1α (HIF1α), a transcription factor that controls cellular response to hypoxic stress, and is essential for BC spread. HIF-1 is implicated in nearly every critical stage of the metastatic progression, including invasion, EMT, intravasation, extravasation, angiogenesis, and the formation of metastatic niches. HIF-1 overexpression has been associated with poor prognosis and increased mortality in BC patients. This is accomplished by controlling the expression of HIF-1 target genes involved in cell survival, angiogenesis, metabolism, and treatment resistance. Studies have indicated that inhibiting HIF-1 has an anti-cancer effect on its own and that inhibiting HIF-1-mediated signaling improves the efficacy of anti-cancer therapy. Approximately 74 % of recognized anti-cancer drugs are sourced from plant species. Studies on anti-cancer characteristics of phytochemicals derived from Moringa oleifera (MO), also known as the ‘Tree of Life’, have revealed a high therapeutic potential for BC. In this review, we have highlighted the various mechanisms through which bioactive compounds present in MO may modulate HIF and its regulatory genes/pathways, to prove their efficacy in treating and preventing BC.
Publisher
Walter de Gruyter GmbH
Subject
Complementary and alternative medicine
Reference98 articles.
1. Ray, SK, Mukherjee, S. Hypoxia-inducible factors-based single nucleotide polymorphism in BC with more cancer susceptibility. Curr Mol Med 2023;23:285–8. https://doi.org/10.2174/1566524022666220513124853. 2. Al Tameemi, W, Dale, TP, Al-Jumaily, RMK, Forsyth, NR. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol 2019;7:4. https://doi.org/10.3389/fcell.2019.00004. 3. Soni, S, Padwad, YS. HIF-1 in cancer therapy: two-decade long story of a transcription factor. Acta Oncol 2017;56:503–15. https://doi.org/10.1080/0284186X.2017.1301680. 4. Rezvani, HR, Ali, N, Nissen, LJ, Harfouche, G, de Verneuil, H, Taïeb, A, et al.. HIF-1α in epidermis: oxygen sensing, cutaneous angiogenesis, cancer, and non-cancer disorders. J Invest Dermatol 2011;131:1793–805. https://doi.org/10.1038/jid.2011.141. 5. Xiong, Q, Liu, B, Ding, M, Zhou, J, Yang, C, Chen, Y. Hypoxia and cancer related pathology. Cancer Lett 2020;486:1–7. https://doi.org/10.1016/j.canlet.2020.05.002.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|